Penehyclidine for PONV Prophylaxis After Strabismus Surgery
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Patients scheduled for elective strabismus surgery under general anesthesia in the First
Affiliated Hospital of Nanjing Medical University will be included in this study.
Patients 1)ASA I or II, 2)aged 3-65 years, 3)scheduled for elective strabismus surgery under
general anesthesia, will be included in the study. Patients 1)had prior PONV, 2)severe motion
sickness, 3)a history of ophthalmic surgery, 4)had received drugs known to have antiemetic
effects, will be excluded from the study.
The primary aim is to evaluate the prophylaxis effect of penehyclidine(a novel long acting
selective anticholinergic agent developed in China) on postoperative nausea and vomiting
after strabismus surgery. Secondary outcomes include the effect of PONV risk factors and
surgical technique on PONV rank score, occurance of oculocardiac reflex, time to extubation.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University